All In Biotech

Drug Trial Radar · NCT06373731

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

ReNEW: A Phase 3, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)

Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 313 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

313

Actual

Start

May 30, 2024

Primary completion

Aug 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Stealth BioTherapeutics Inc.Industry
Sponsor type
Industry
First posted
Apr 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug, and what is the safety and tolerability of elamipretide daily subcutaneous injections. Participants will receive either once daily subcutaneous doses of 40mg elamipretide or placebo and the two treatment groups will be compared.

Conditions

  • Age Related Macular Degeneration (ARMD)

Interventions

  • ElamipretideDrug

    Subjects will receive once daily SC doses of 40 mg elamipretide for 96 weeks

  • PlaceboDrug

    Subjects will receive once daily SC doses of Placebo 96 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Week 48 Rate of change in the macular area of photoreceptor lossTime frame: Baseline, Week 48

Locations

53 sites in 8 countries. Site status is shown where the registry gives one.

  • Associated Retina Consultants

    Phoenix, Arizona

  • Barnet Dulaney Perkins Eye Center

    Sun City, Arizona

  • Retina Associates of Southern California

    Huntington Beach, California

  • Retina Consultants of San Diego

    Poway, California

  • Retinal Consultants Medical Group

    Sacramento, California

  • Orange County Retinal Medical Group

    Santa Ana, California

  • Bay Area Retina Associates

    Walnut Creek, California

  • Retina Consultants of Southern Colorado

    Colorado Springs, Colorado

  • Connecticut Eye Consultants, P.C.

    Danbury, Connecticut

  • Vitreo Retinal Associates

    Gainesville, Florida

  • Florida Retina Institute

    Orlando, Florida

  • Retina Vitreous Associates of Florida

    St. Petersburg, Florida

  • University Retina and Macula Associates

    Oak Forest, Illinois

  • Associated Vitreoretinal and Uveitis Consultants

    Carmel, Indiana

  • Mid Atlantic Retina Specialist

    Hagerstown, Maryland

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts

  • Kellogg Eye Center

    Ann Arbor, Michigan

  • Retina Consultants of Minnesota

    Minneapolis, Minnesota

  • Mid Atlantic Retina

    Cherry Hill, New Jersey

  • NJ Retina

    Teaneck, New Jersey

  • Retina Vitreous Center

    Edmond, Oklahoma

  • Retina Northwest, PC

    Portland, Oregon

  • Retina Research Institute of Texas

    Abilene, Texas

  • Austin Clinical Research, LLC

    Austin, Texas

  • Retina Consultants of Texas

    Bellaire, Texas

  • Valley Retina Institute

    McAllen, Texas

  • Texas Retina Associates of Plano

    Plano, Texas

  • Medical Center Ophthalmology Associates

    San Antonio, Texas

  • Retina Consultants of Texas

    The Woodlands, Texas

  • Emerson Clinical Research Institute

    Falls Church, Virginia

  • Pacific Northwest Retina, PLLC

    Silverdale, Washington

  • Axon Clinical, s.r.o.

    Prague, Czechia

  • Augenzentrum am St. Franziskus-Hospital

    Münster, Germany

  • Klinik und Poliklinik für Augenheilkunde- Universitätsklinik Regensburg

    Regensburg, Germany

  • Department für Augenheilkunde

    Tübingen, Germany

  • University Of Debrecen Eye Center

    Debrecen, Hungary

  • Ganglion Medical Center

    Pécs, Hungary

  • University of Szeged, Department of Ophthalmology

    Szeged, Hungary

  • Hospital Luigi Sacco Ophthalmology Dept

    Milan, Italy

  • IRRCS Ospendale San Raffaele

    Milan, Italy

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.